See every side of every news story

Published 2 days ago • loading... • Updated 2 days ago

Pfizer Discontinues Hemophilia B Gene Therapy Beqvez Amidst Weak Demand

Summary by healtheconomics.com

Pfizer has announced its decision to cease the development and commercialization of Beqvez, its gene therapy for hemophilia B, citing weak demand as the primary reason. Originally developed by Spark Therapeutics and licensed by Pfizer in 2014, Beqvez received U.S. approval in April for treating hemophilia B, a less common form of the genetic bleeding disorder. However, the treatment failed to gain significant traction, prompting Pfizer to shift …

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

healtheconomics.com

Pfizer Discontinues Hemophilia B Gene Therapy Beqvez Amidst Weak Demand

Pfizer has announced its decision to cease the development and commercialization of Beqvez, its gene therapy for hemophilia B, citing weak demand as the primary reason. Originally developed by Spark Therapeutics and licensed by Pfizer in 2014, Beqvez received U.S. approval in April for treating hemophilia B, a less common form of the genetic bleeding disorder. However, the treatment failed to gain significant traction, prompting Pfizer to shift …

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated1 day agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

healtheconomics.com broke the news in 2 days ago on Friday, February 21, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics